| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-443
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 |
| filingDate |
2013-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2017-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-104822392-B |
| titleOfInvention |
Suppress the method that IL 22 is expressed in the T cells of activation |
| abstract |
The present invention relates to the method for suppressing proinflammatory cytokine interleukin-22 2 (IL 22) up-regulated expression in activation and differentiation people's T cells, described up-regulation is induced by phosphodiesterase 4 (PDE4) inhibitor for applying therapeutically effective amount.The Vitamin D receptor agonist for the amount for being enough to suppress the up-regulated expressions of IL 22 is sequentially or simultaneously applied in the administration that this method is included with PDE4 inhibitor. |
| priorityDate |
2012-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |